Androgen deprivation therapy causes a paradoxical elevation of matrix metalloproteinases (MMPs) including MMP-9 resulting in aggressive tumor phenotype in many patients with prostate cancer. In this study, we have evaluated a novel antisense phosphorodiamidate Morpholino oligomer (PMO) targeted against MMP-9 in models of angiogenesis and in human prostate xenograft in athymic mice. The treatment of androgen-independent DU145 human prostate cells with a 21-mer MMP-9 antisense PMO caused a dose-dependent inhibition of cell proliferation compared to scrambled or MMP-2 antisense PMO at similar concentrations. This was associated with decreases in MMP-9 expression, gelatinolytic activity and increased stability of the insulinlike growth factor-binding protein (IGFBP-3), a proapoptotic factor and MMP-9 substrate. In vitro invasion assays revealed a 40-60% inhibition of DU145 cell invasion in the presence of 25 mM MMP-9 antisense PMO. A significant decrease in endothelial cell migration and vascularization was observed in the Matrigel plug assay in mice when treated intraperitoneally with 300 mg/day MMP-9 antisense for 21 days. In the highly vascular DU145 tumor xenografts, MMP-9 inhibition caused decreased tumor growth with regression in 50% of the animals. Histological analysis revealed increased apoptosis and fibrous tissue deposits in the MMP-9 antisense-treated tumors compared to the scrambled and saline controls. No apparent toxicity or mortality was associated with the MMP-9 PMO treatment. In summary, the MMP-9 antisense PMO inhibited in vitro prostate cancer cell proliferation, invasion and in vivo angiogenesis. These data establish the feasibility of developing a site-directed, nontoxic antisense therapeutic agent for inhibiting local invasion and metastasis.
P
rostate cancer is the second most common cause of mortality among men in the Western world. 1 Androgen ablation by surgical castration (orchiectomy), administration of antiandrogens/chemical castration or a combination of these methods represents the most frequently adopted clinical procedure in the treatment of advanced prostate cancer patients. 2, 3 The proliferation of prostate tumor cells is often initially androgendependent, but the frequent development of androgeninsensitive late-stage prostate cancer renders androgensuppressing treatments ultimately ineffective. A paradoxical increase in the levels of matrix metalloproteinase-9 (MMP-9) has been reported to be associated with androgen deprivation and the resultant aggressive phenotype in prostate cancer patients. 4 MMP-9 is a member of a unique multigene family of neutral proteinases that have a zinc ion at their active site.
These proteolytic enzymes have been grouped on the basis of substrate specificity in the extracellular matrix, (a) fibrillar collagenases (MMP-1, -8, -13); (b) type IV collagenases (MMP-2, -9); (c) stromelysins that can degrade proteoglycans, fibronectin, laminin (MMP-3, -10, -11); and (d) membrane associated (MMT-MMPs). The MMPs are secreted as latent forms and activation occurs postcleavage by various proteases at a conserved site on the amino-terminus of the proenzyme. In addition to gene expression and proenzyme activation, MMPs are regulated by the presence of specific tissue inhibitors, TIMPS. 5 The MMPs are produced by a variety of tissues and are involved in several physiological processes including pregnancy, bone resorption, parturation, wound healing and mammary development. However, the overexpression and activation of MMPs, particulary MMP-9, has been linked with a range of pathological processes involved in the breakdown and remodeling of the ECM, which includes cardiovascular insults (myocardial infarction, 6 vein graft stenosis, Primary cultures of human prostate tumors have been observed to secrete high levels of MMP-2 and -9 protein and mRNA and low levels of TIMPs, thus creating an excess balance of proteases. [13] [14] [15] MMP-9 null mice or mice overexpressing TIMP1 have been observed to have fewer cancers. 16 MMP-9 has also been shown to interact with the insulin-like growth factor (IGF) autocrine loop in the prostate cells by acting as a protease of IGFbinding proteins, particularly IGFBP-3 identified to have proapoptotic and potential tumor-suppressive functions. 17, 18 A decrease in serum levels of intact IGFBP-3, the predominant IGF-binding protein in adult serum, has been reported in patients with prostate cancer. [19] [20] [21] Since prostate cancer cells exhibit very slow growth kinetics, chemotherapy is of little value and is only useful for symptom palliation. Therefore, targeting the metastatic growth of prostate cancer with a site-directed, nontoxic drug that inhibits tumor cells from establishing metastatic colonies is an attractive therapeutic option. Nontoxic inhibitors of MMP that decrease tumor cell invasion and neoangiogenesis are potential drug candidates. Although a number of laboratories are engaged in developing such therapeutic agents for prostate cancer, few are currently in clinical trials and many have failed due to serious adverse events. 22, 23 In this study, we have designed and tested the efficacy of a specific and novel MMP-9 antisense phosphorodiamidate Morpholino oligomer (PMO) in DU145 androgen-independent prostate cancer cells and in vivo models of angiogenesis, invasion and tumorigenesis. We report that the MMP-9 antisense PMO specifically inhibits MMP-9 protein expression, enzymatic activity and causes increased stabilizaton of a proapoptotic factor, IGFBP-3, in DU145 cells. Further, subcutaneous or systemic treatment with the specific PMO caused no serious adverse events or toxicity in the animals and MMP-9 antisense PMO caused a decrease in tumor cell invasion, angiogenesis and tumor progression in the DU145 xenograft murine model.
Materials and Methods

Oligomers
PMOs were synthesized at AVI BioPharma Inc. (Corvallis, OR) as previously described. 24 Purity was 495% as determined by reverse-phase HPLC and MALDI TOF mass spectroscopy. The base composition of the oligomers are shown in Table 1 .
Cell culture
HeLa and androgen-insensitive DU145 cell lines were obtained from ATCC (Rockville, MD). HeLa cells were cultured in DMEM/F12 and DU145 cells in RPMI media at 371C under 5% CO 2 . Both media (Hyclone Laboratories, Logan, UT) were supplemented with 10% FBS and antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin, 0.25 mg/ml amphotericin B). Fetal bovine serum (FBS) and the antibiotics were purchased from Life Technologies (Gaithersburg, MD). Plasmid-based test system for screening PMO antisense activity A fusion construct was generated by subcloning 29 bases of the 5 0 untranslated region, AUG translational start site, and the first 16 bases of the protein coding sequence of MMP-9 gene followed by luciferase in the pCiNeo expression vector (Promega, Madison, WI). The AUG start site of luciferase was subjected to in vitro sitedirected mutagenesis resulting in a single start site in the MMP-9 leader. This fusion construct was named pCiNeo MMP-9-LucnA. This plasmid features a T7 promoter capable of generating in vitro transcribed RNA from a cloned insert for use in cell-free rabbit reticulocyte in vitro translation reactions and a CMV promoter for constitutive expression in mammalian cells. In vitro transcription was carried out with T7 Mega script (Ambion, Austin, TX). Cell-free luciferase assay. In vitro translation was performed by mixing the rabbit reticulocyte lysate with known amounts of antisense, scrambled PMOs or vehicle (water) followed by addition of a known amount of the MMP-9/Luc RNA (B1 nM final conc.). The Promega luciferase assay reagent protocol was followed. The percent inhibition of luciferase activity compared to control was calculated based on readings from a luminometer (Cardinal, Santa Fe, NM).
Animals
Luciferase assay in cell culture. Confluent HeLa cells were transiently transfected with the pCiNeoMMP-9-LucnA plasmid using Lipofectamine (Gibco BRL) according to the manufacturer's directions. The cells were trypsinized 24 hours later and 6 Â 10 5 cells/well were plated in six-well plates. The cells were allowed to adhere overnight and scrape loaded with vehicle or PMOs at different concentrations. 25, 26 Cell lysates were prepared 24 hours later, normalized for protein content and luciferase activity was determined using a luminometer.
Gelatin zymography and IGFBP-3 immunoblot
A total of 1 Â 10 6 cells were seeded per well into a six-well plate in serum containing media and allowed to incubate overnight at 371C and 5%CO 2 . The oligomers were delivered into the DU145 by scrape loading as described earlier. 26 The cells were scraped in the presence or absence of PMO in 1 ml SFM+0.1% BSA and the scraped cells were transferred into 25-mm cell culture inserts of 1 mm pore size and polyethylene terephthalate track-etched membranes (Cat. # 40567, BD Biosciences, Palo Alto, CA) as described in an earlier study. 27 The inserts were placed in companion plates containing serum-containing media in the wells. The conditioned media from the inserts were collected 24 hours post-treatment. MMP-9 enzymatic activity in the prostate cancer cells was analyzed by using gelatin as a substrate in zymograms. The media were normalized for cell number and run on a 10% SDS/gelatin gel (Invitrogen, Carlsbad, CA) under nonreducing and no heating conditions.
The conditioned media were also run on a 10% SDS-PAGE and immunoblotted and probed with the IGFBP-3 monoclonal antibody (Diagnostic Systems Laboratory, Webster, TX) as previously described. 18 The membranes were washed three times with wash buffer (1 Â PBS, 0.1% Tween 20), and then incubated for 30 min with appropriate secondary antibody conjugated to horseradish peroxidase (1:5000 dilution). The membranes were washed and the immunoreactive proteins were visualized using an enhanced chemiluminescence detection system (Amersham, Arlington Heights, IL).
Western immunoblot
The various PMOs in serum-free media were delivered into DU145 cells by the scrape loading procedure as previously described. 26 After 48 hours, the conditioned media from these cells were collected and concentrated and then loaded on a 7.5% SDS-PAGE under reducing conditions. The immunoblots were probed with the MMP-9 monoclonal antibody (Neomarkers, Fremont, CA) at 1:1000 dilution in blocking buffer (20 mM Tris base, 150 mM NaCl, 4% nonfat milk, and 0.1% Tween 20) overnight at 41C. The membranes were washed three times with wash buffer (1 Â PBS, 0.1% Tween 20), and then incubated for 1 hour with the appropriate secondary antibody conjugated with horseradish peroxidase (1:2000) . The membranes were washed and the immunoreactive proteins were visualized using an enhanced chemiluminescence detection system (Amersham, Arlington Heights, IL).
Cell viability assay
At different time intervals after the treatment of cells with PMO or appropriate vehicle in serum-free media, 1:10 dil of 5 mg/ml MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma Chemical Co.) was added to each well in a six-well plate at 371C until blue coloration started to appear in the cells. The medium was then aspirated and replaced with dimethyl sulfoxide. The absorbance was read at 540 nm in a Molecular Devices plate reader and analyzed by the SOFTmax Program.
Invasion assay
In total, 5 Â 10 5 DU145 cells were seeded per well in a sixwell plate. Cells were scraped when 90-95% confluent in SFM+0.1%BSA with vehicle or PMO and transferred into 8 mm control inserts or Matrigel-precoated inserts (BD Bioscience, Palo Alto, CA). The inserts were placed in companion wells containing RPMI+10%FBS as a chemoattractant. The cells were incubated for 22 hours. The noninvading cells on the upper surface of the membrane of the insert were removed by scrubbing. The cells on the lower surface of the membrane were stained with Diff-Quik TM stain. The membranes were fixed and the cells were counted at Â 200 magnification under a light microscope (5-10 fields were counted in each experiment). Data are expressed as the % invasion through the Matrigel matrix membrane relative to migration through the control membrane.
Matrigel plug assay. Matrigel was subcutaneously (s.c.) injected alone or mixed with VEGF-500 ng/ml, FGF 500 ng and Heparin (10 U) in a total volume of 500 ml into the dorsal hind flank of athymic male mice. Groups of three mice were injected i.p. with saline, scrambled PMO or MMP-9 antisense PMO at 300 mg /day for three cycles of 5 days/week. At the end of the treatment cycles, the Matrigel plug was removed, formalin fixed, parrafin embedded and the sections were stained with Trichrome Masson.
In vivo tumor studies. In total, 5 Â 10 6 DU145 cells were suspended in 150 ml RPMI and injected via a 25-gauge needle into the s.c. space of the flank region of 4-5-week old athymic male mice. All animals were anesthetized with isofluorane before injection of cells.
Treatment protocols
The experiment was started when the tumors were latent and the tumor volumes were about 40-90 mm 3 . Groups of mice (7) (8) (9) were randomly assigned to different groups and received intratumoral injections of vehicle (saline control), or scrambled oligomer (PMO-37-6) or MMP-9 antisense (PMO 37-3) 5 days a week for a period of two cycles. Tumors were measured using calipers, and the tumor volume was calculated by using the formula (Length x Width 2 /2, where L4W). At the end of the experiment, the animals were euthanized, tumors were excised and weighed, and tumor burden was calculated. In these experiments, the toxicity was evaluated on the basis of mortality rate, changes in CBC counts, body weight and serum chemistry. A complete autopsy of the mice was conducted to rule out macroscopic side effects. The tumor tissues were fixed in 10% formalin and paraffin embedded. Six-mm-thick sections of paraffin-embedded tumor specimens were stained with hematoxylin and eosin.
Results
MMP-9 antisense PMO causes sequence-specific inhibition of MMP-9 protein
In order to ascertain the sequence specificity of the MMP-9 PMO, a plasmid-based test system was used for both cell-free and cellular screening. A fusion construct, pCiNeo MMP-9-LucnA, was generated by subcloning a small segment (45 bases) of the MMP-9 gene that includes the AUG translation start site, followed by luciferase into the pCiNeo expression vector. In vitro translation was performed by mixing the rabbit reticulocyte lysate with known amounts of antisense, scrambled oligomers or vehicle (water) followed by the addition of a known amount of the MMP-9/Luc in vitro transcribed RNA. The percent inhibition of luciferase activity in the presence of various concentrations of the PMO compared to the vehicle control was calculated based on the readings from a luminometer. The data in Figure 1a reveal a dosedependent inhibition of luciferase activity in the presence of increasing concentrations of the antisense MMP-9 PMO. This inhibition was sequence-specific as the scrambled PMOs and an antisense PMO against MMP-2 showed no such effect. Similarly, in HeLa cells transfected with the pCiNeo MMP-9-LucnA construct, the MMP-9 antisense oligomer caused a dose-dependent inhibition of the translation of the MMP-9 luciferase RNA (Fig 1b) .
Inhibition of MMP-9 decreases cell viability in DU145 cells associated with increased IGFBP-3 stability
Treatment of the DU145 androgen-independent prostate cancer cells with different doses of MMP-9 antisense (PMO-37-3) caused a decrease in cell proliferation as determined by the MTT assay (Fig 2a) . A significant decrease (40-50%) in the number of viable cells was observed 24 hours after treatment with 25 mM MMP-9 antisense agent. This effect was not seen after treatment with similar concentrations of an antisense PMO against MMP-2, a related MMP, or with scrambled controls. Inhibition of cell proliferation after treatment with 25 mM MMP-9 AS PMO was also observed in PC-3 (androgenindependent) cells, but not in LNCaP (androgen-responsive) prostate cancer cells (data not shown). Analysis of the conditioned media from the MMP-9 antisense-treated cells revealed decreased MMP-9 levels (Fig 2b) and gelatinolytic activity (Fig 2c) in the MMP-9-treated cells compared to scrambled-or vehicle-treated cells.
In addition, the conditioned media from vehicle-treated cells showed significantly higher levels of the IGFBP-3 19 kDa proteolytic fragment compared to the conditioned media of the MMP-9 antisense-treated cells (Fig 2d) , MMP-9 inhibition in tumor and angiogenesis models CA London et al indicative of decreased IGFBP-3 proteolysis when MMP-9, a potent IGFBP-3 protease, is inhibited in the DU145 cells.
Inhibition of tumor cell invasion and angiogenesis by MMP-9 antisense PMO
The effect of MMP-9 antisense PMO on the invasive activity of the DU145 tumor cells in reconstituted basement membrane components was assayed using an in vitro Matrigel invasion assay. The MMP-9 antisense treatment caused a significant decrease in the invasive activity of the DU145 cells (45% inhibition at 25 mM; Fig 3) . The murine Matrigel plug assay was used to assess the effect of MMP-9 inhibition on new blood vessel formation in vivo. Proangiogenic factors (VEGF, FGF) and anticlotting factor (heparin) were mixed with Matrigel and implanted s.c. on the dorsal hind flank of mice in the presence of saline, scrambled or MMP-9 antisense PMO. Intraperitoneal administration of saline or the oligomers for a period of three cycles of 5 days was started immediately after the implantation of the Matrigel plug. At the end of the treatment cycles, the Matrigel plug was removed and processed with Masson's Trichrome that stains the Matrigel blue and the endothelial cells red. The data in Figure 4 reveal the presence of higher levels of endothelial cells (stained as red filaments and cells) in saline (Fig 4b) and scrambled-treated PMO (Fig 4c) compared to the MMP-9-antisense-treated (Fig 4d) , which was similar to the basal invasion (Fig 4a) .
MMP-9 antisense inhibits growth and vascularity of DU145 tumor xenografts
The antitumor activity of the MMP-9 antisense PMO was evaluated in DU145 s.c. xenografts in athymic mice. The oligomers or saline were administered i.t. based on earlier studies [28] [29] [30] as two cycles of 5 day injections at 300 mg / mice dose in latent tumors (average initial tumor volumes of 40-90 mm 3 ). Changes in DU145 tumor growth between saline, scrambled control and MMP-9 antisense are compared in Table 2 . At the end of the treatment cycles, tumor volumes of the animals injected with MMP-9 antisense PMO were significantly smaller (88724) than in saline (163760.7) or scrambled control (204725) groups corresponding to a 50-60% inhibition (Po.05). In terms of tumor progression, all the saline and scrambled PMOtreated tumors started developing vascular lesions and nodular growth from day 9, compared to only one such case in the MMP-9 antisense-treated group (Fig 5) . In the MMP-9 inhibition in tumor and angiogenesis models CA London et al MMP-9 antisense PMO-treated group, tumors completely regressed in 50% of the animals, and in the others the tumor growth rate was significantly decreased compared to the control groups. The MMP-9 antisense-treated tumor weights were also significantly lower as compared to the controls (Table 2) . No mortality or significant change in body weight was observed in any of the groups during the course of the experiment. No macroscopic damage was evident in the area surrounding the s.c. tumor, liver, lungs, heart and kidneys of the animals in this experiment (data not shown). Representative hematoxylin/eosin-stained histological sections from the center of the MMP-9 antisense, saline-and scrambled-treated tumors are shown in Figure 5b (panel I). The MMP-9 antisense-treated tumor sections have smaller cells, fewer mitotic figures and anaplastic cells, and increased apoptotic bodies compared to the scrambled-and saline-treated tumor sections under similar power field (Table 3) . Trichrome Masson staining showed increased deposits of fibrous tissue (stains blue) in the tumor sections of the MMP-9 antisense-treated animals (Fig 5b, panels II, III) .
Discussion
We report herein the design and development of a specific 21-mer antisense PMO directed against the 5 0 untranslated region and the translational start site of the human MMP-9 gene. Various PMO sequences were screened in a plasmid-based test system of both cell-free and cellular translation, where the MMP-9 antisense PMO specifically inhibited the expression of a MMP-9-luciferase fusion protein. This antisense PMO also caused specific inhibition of the endogenous MMP-9 protein levels and enzymatic activity in DU145 prostate cancer cells. A significant decrease in DU145 cell invasiveness was observed after treatment with MMP-9 antisense PMO in both in vitro invasion and Matrigel plug assay in athymic mice compared to the vehicle and scrambled PMO control oligomer.
It is widely recognized that tumor growth beyond 1-2 mm requires the recruitment of blood supply through a process of angiogenesis. 31 Under physiological conditions, angiogenesis is confined to the female reproductive cycle, pregnancy and wound healing and is tightly regulated through a balance between the expression of proangiogenic and antiangiogenic factors. 32 The restriction of tumor cell angiogenesis offers the prospect of selective antiangiogenic therapy with minimal toxicity to normal cells. Modulators of the extracellular matrix microenviroment, like MMPs, are attractive targets to inhibit tumor invasion and angiogenesis.
11,33 MMP-9 elevation seems to be associated with androgen ablation in prostate cancer patients. 4 In addition, MMP-9, like prostate-specific antigen, 19 cleaves IGFBP-3. 34 The proteolytic fragments of IGFBP-3 are unable to modulate the bioavailability of endogenously produced IGF mitogenic factors as effectively as intact IGFBP-3. [35] [36] [37] The treatment of DU145 prostate cancer cells with the MMP-9 antisense PMO caused a dose-dependent inhibition of cell proliferation, with about 40% inhibition occurring at 20 mM dose compared to a scrambled or an MMP-2 antisense PMO at similar concentrations. This was associated with decreased levels of IGFBP-3 proteolytic fragments in conditioned media of cells treated with the MMP-9 antisense PMO. These results are supported by earlier observations by Manes et al, 34 that a balance between the autocrine secretion of IGF ligands, IGFBP-3 and MMP-9 levels is critical for optimal cell growth in the case of DU145 cells. Further studies are underway using this MMP-9 AS PMO as a tool to understand the compartmentalization of MMP-9 and its interaction with the members of the IGF pathway.
The new generation of oligomers with phosphorodiamidate Morpholino backbone possess a novel structure, wherein the deoxyribose moiety of DNA is replaced with a six-membered morpholine ring and the charged phosphodiester internucleoside linkages are replaced with phosphorodiamidate linkages. 24, 38 Hence, the PMO are nonionic and this neutral chemistry avoids a variety of potentially significant limitations observed with the traditional oligonucleotides. 39 Unlike the phosphorothiate analogs, PMO compounds do not serve as RNaseH substrates. 39, 40 Multiple mechanisms of action of the PMOs have been identified, including steric blockade of ribosomal assembly during translation initiation by PMO targeting at the AUG start site as well as interference with intron-exon splicing of pre-mRNA when PMO is targeted to the splice donor or acceptor sites thus blocking the translation of selected mRNA. 41 The translational arrest a b c d Figure 4 In vivo Matrigel plug assay. Matrigel alone (a); Matrigel +VEGF (500 ng/ml)+FGF (500 ng)+Heparin (10 U) plug treated intraperitoneally with saline (b); scrambled PMO (c) or MMP-9 antisense PMO (d). Intratumoral injections of 300 mg /mice (5 days on and 2 days off cycle) of each compound for a period of 15 days. No deaths occurred during this period. Tumors were measured using calipers, and the tumor volume was calculated using the formula (Length Â Width MMP-9 inhibition in tumor and angiogenesis models CA London et al mediated by the PMO:mRNA duplex has been evaluated by classical methods in enzymology such as LineweaverBurke plots. When the PMO is directed at the 5 0 untranslated region, the inhibition is noncompetitive, whereas biphasic, mixed inhibition is observed when directed at the AUG translation initiation start site. 42 In this study, intratumoral administration of the MMP-9 antisense PMO in DU145 xenograft tumor-bearing athymic mice caused a significant inhibition of tumor growth and lesion formation. A significant decrease in the number of anaplastic and mitotic cells, and an increase in apoptotic cells and fibrous tissue deposits were observed in the MMP-9 antisense-treated tumor sections compared to the saline and scrambled PMO-treated tumors. In earlier studies, we have also characterized the in vivo bioavailability and biodistribution of various antisense PMO sequences by immunoblots, HPLC-based quantitation and in situ fluorescence photomicrographs in cancer models employing intratumoral 30 and intraperitoneal 26, 43 routes of administration. PMO bioavailability has also been shown with oral 44 and transdermal 45 routes of administration in other animal models.
The safety of the PMOs has been extensively established. We have previously reported the safety profile of a 20-mer antisense PMO targeting the c-myc gene in a human Phase I clinical trial, which revealed that the intravenous administration of the antisense PMO did not cause any untoward toxicity (NCI Common Toxicity Criteria) or mortality in healthy human volunteers. 30 Results from these trials also demonstrated that the commonly observed hematological side effects related to various phosphorothioate-based antisense agents were not seen with the PMO chemistry. [46] [47] [48] The present study further supports this safety profile as treatment of mice for 3 weeks did not cause mortality or any untoward toxicity.
In summary, this report demonstrates the efficacy of a novel antisense-based inhibitor of MMP-9 expression and these results warrant further investigations in disease conditions where MMP-9 has been implicated in addition to its effects in other tumor/metastasis models.
